Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Oncology
Dracen launches for immunometabolism
by Lisa M. Jarvis
April 2, 2018
| A version of this story appeared in
Volume 96, Issue 14
Dracen Pharmaceuticals, a Baltimore-based biotech firm focused on immunometabolism, has come out of stealth with a $40 million funding round. Deerfield Management committed the lion’s share of the cash. Dracen is developing glutamine antagonists to be used alone and in combination with a class of immuno-oncology drugs called checkpoint inhibitors. The compounds in its pipeline were discovered at Johns Hopkins University and the Institute of Organic Chemistry & Biochemistry of the Czech Academy of Sciences.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter